Titlebook: Drugs for the Treatment of Parkinson’s Disease; Donald B. Calne (Head) Book 1989 Springer-Verlag Berlin Heidelberg 1989 Parkinson.adverse

Kaleidoscope

,The Neurochemical Basis of the Pharmacology of Parkinson’s Disease,e marketed preparation, or the impenetrability of the blood-brain barrier to DA. From the very wide variety of drugs and (tissue) preparations that have been proposed as potential remedies for PD, it can be concluded that the results of this century-long empirical approach to pharmacotherapy of PD w

RAGE

alcohol-abuse

Ceremony

物質(zhì)

鳴叫

Kate J. Bowers,Shane D. Johnson of symptomatic therapy for neurodegenerative disease as effectively targeted for the essential pathophysiology as is LD against PD. In the last two decades, use of LD has become so pervasive that it is virtually impossible to study the natural history of PD without the intervening factor of LD therapy.

CON

Benjamin Schwessinger,John P. Rathjenaranoia, insomnia, and an awakening effect. The dyskinesias were chorea, myoclonus, hemiballism (ipsilateral to the side of a prior thalamotomy), and dystonia. These adverse effects subsided with lowering of the dosage.

評(píng)論者

Benjamin Schwessinger,John P. Rathjeness of Parkinson’s disease. In this chapter, the clinical experience to date of the use of .-deprenyl in regard to its pharmacologic properties, indications for use, and effectiveness in the control of parkinsonism will be discussed.

rheumatology

Cardioplegia